ATE378061T1 - Neurotrophe faktoren zur behandlung einer dysfunktion peripherer nerven im beckenbereich - Google Patents

Neurotrophe faktoren zur behandlung einer dysfunktion peripherer nerven im beckenbereich

Info

Publication number
ATE378061T1
ATE378061T1 AT00929587T AT00929587T ATE378061T1 AT E378061 T1 ATE378061 T1 AT E378061T1 AT 00929587 T AT00929587 T AT 00929587T AT 00929587 T AT00929587 T AT 00929587T AT E378061 T1 ATE378061 T1 AT E378061T1
Authority
AT
Austria
Prior art keywords
surgery
neurotrophic factors
dysfunction
pelvic area
treatment
Prior art date
Application number
AT00929587T
Other languages
English (en)
Inventor
Mart Saarma
Antti Laurikainen
Jukka Hiltunen
Matti Airaksinen
Erik Klinge
Original Assignee
Licentia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licentia Ltd filed Critical Licentia Ltd
Application granted granted Critical
Publication of ATE378061T1 publication Critical patent/ATE378061T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
AT00929587T 1999-05-27 2000-05-26 Neurotrophe faktoren zur behandlung einer dysfunktion peripherer nerven im beckenbereich ATE378061T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI991197A FI991197A0 (fi) 1999-05-27 1999-05-27 Neurotrooppiset tekijät lantionalueen ääreishermoston toimintahäiriön hoitamisessa

Publications (1)

Publication Number Publication Date
ATE378061T1 true ATE378061T1 (de) 2007-11-15

Family

ID=8554739

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00929587T ATE378061T1 (de) 1999-05-27 2000-05-26 Neurotrophe faktoren zur behandlung einer dysfunktion peripherer nerven im beckenbereich

Country Status (14)

Country Link
EP (1) EP1181042B8 (de)
JP (1) JP2003500455A (de)
KR (1) KR20020016805A (de)
CN (1) CN1365285A (de)
AT (1) ATE378061T1 (de)
AU (1) AU776275B2 (de)
CA (1) CA2373726A1 (de)
DE (1) DE60037111T2 (de)
ES (1) ES2295027T3 (de)
FI (1) FI991197A0 (de)
IL (1) IL146346A0 (de)
NO (1) NO20015751L (de)
NZ (1) NZ515379A (de)
WO (1) WO2000072871A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1365794A2 (de) 2000-07-21 2003-12-03 Lue, Tom Vorbeugung und behandlung von störungen der sexuellen erregbarkeit
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
JP2009525319A (ja) 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
TW201034684A (en) * 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
DE102011051868B4 (de) * 2011-07-15 2013-02-21 ITM Isotopen Technologien München AG Verfahren zur Herstellung trägerfreier hochreiner 177Lu-Verbindungen sowie trägerfreie 177Lu-Verbindungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2109598A1 (en) * 1991-05-21 1992-11-26 Finn Hallbook Therapeutic and diagnostic methods based on neurotrophin-4- expression
DE69732350T2 (de) * 1996-03-14 2005-12-22 Washington University Persephin und verwandte wachstumsfaktoren
WO1998002178A1 (en) * 1996-07-12 1998-01-22 Massachusetts Institute Of Technology Methods of controlling axonal growth
CA2279577A1 (en) * 1997-02-04 1998-08-06 Valentis, Inc. Treatment for urinary incontinence using gene therapy techniques
AU730430B2 (en) * 1997-02-18 2001-03-08 Genentech Inc. Neurturin receptor

Also Published As

Publication number Publication date
CA2373726A1 (en) 2000-12-07
KR20020016805A (ko) 2002-03-06
AU4761000A (en) 2000-12-18
EP1181042B1 (de) 2007-11-14
NZ515379A (en) 2004-04-30
JP2003500455A (ja) 2003-01-07
EP1181042A1 (de) 2002-02-27
CN1365285A (zh) 2002-08-21
NO20015751D0 (no) 2001-11-26
IL146346A0 (en) 2002-07-25
AU776275B2 (en) 2004-09-02
DE60037111D1 (de) 2007-12-27
ES2295027T3 (es) 2008-04-16
DE60037111T2 (de) 2008-10-02
WO2000072871A1 (en) 2000-12-07
FI991197A0 (fi) 1999-05-27
NO20015751L (no) 2001-12-20
EP1181042B8 (de) 2008-01-23

Similar Documents

Publication Publication Date Title
IS7770A (is) Hlutleysandi mótefni gegn GDF-8 og notkun theirra
WO2002041837A3 (en) Treatment of mucositis
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE69634748D1 (de) Verwendung von fibroblasten-wachstumsfaktor analogen zur stimulation des knochenwachstums
DE69827621D1 (de) Immunogene zusammensetzungen gegen den cck-b-gastrin-rezeptor und verfahren zur behandlung von tumoren
EP1837025A3 (de) Verfahren zur Krebsbehandlung mit Kinaseinhibitoren
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
EP1108426A3 (de) Anwendung von Prostaglandinagonisten zur Behandlung der Erektionstörungen und Impotenz
ATE378061T1 (de) Neurotrophe faktoren zur behandlung einer dysfunktion peripherer nerven im beckenbereich
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE255411T1 (de) Hyaluronsäurerezeptoren bindende stoffe und deren verwendung zur behandlung von tumoren und restenose
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
WO1999016406A3 (en) Therapeutic method
WO2000078328A3 (de) VERWENDUNG VON WACHSTUMSHORMON (hGH) ZUR THERAPIE SEXUELLER FUNKTIONSSTÖRUNGEN
DE69727491D1 (de) Verfahren zur verabreichung von wachstumsfaktoren
RU2244551C2 (ru) Способ лечения моторно-вегетативных нарушений у детей
DE60122781D1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
WO2001012127A3 (en) TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
Hayase et al. A Case of Blunt Traumatic Arteriovenous Malformation of the Forearm
MD1732F1 (en) Method of prognosticating the duodenal ulcerous disease evolution
UA47640U (uk) Спосіб заміщення пострезекційних дефектів, що утворилися при сегментарній резекції кісткових кіст у дітей
ATE380884T1 (de) Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties